CN Patent

CN116212027A — 一种调控Treg细胞内铁水平的试剂的用途

Assigned to Westlake University · Expires 2023-06-06 · 3y expired

What this patent protects

本发明提供了一种调控Treg细胞内铁水平的试剂的用途，通过靶向调节性T细胞(regulatory T cell,Treg)铁离子代谢途径，调控Treg细胞分化，实现抑制肿瘤发生和炎性结肠炎(Inflammatory bowel disease，IBD)发展的新型治疗策略。本发明发现铁离子代谢对肿瘤微环境中Treg细胞的分化极为关键，阻断Treg细胞中的铁吸收途径能显著抑制肿瘤组织的生长，靶向性强。其次，还发现IBD患者肠道中短链脂肪酸‑戊酸的水平明显下降，补充戊酸能促进肠道Treg细胞铁离子吸收，同时缓解由IBD诱发的结肠炎症和缺铁性贫血，具有安全,高效…

USPTO Abstract

本发明提供了一种调控Treg细胞内铁水平的试剂的用途，通过靶向调节性T细胞(regulatory T cell,Treg)铁离子代谢途径，调控Treg细胞分化，实现抑制肿瘤发生和炎性结肠炎(Inflammatory bowel disease，IBD)发展的新型治疗策略。本发明发现铁离子代谢对肿瘤微环境中Treg细胞的分化极为关键，阻断Treg细胞中的铁吸收途径能显著抑制肿瘤组织的生长，靶向性强。其次，还发现IBD患者肠道中短链脂肪酸‑戊酸的水平明显下降，补充戊酸能促进肠道Treg细胞铁离子吸收，同时缓解由IBD诱发的结肠炎症和缺铁性贫血，具有安全,高效的优点。

Drugs covered by this patent

Patent Metadata

Patent number
CN116212027A
Jurisdiction
CN
Classification
—
Expires
2023-06-06
Drug substance claim
No
Drug product claim
No
Assignee
Westlake University
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.